APO®-LENALIDOMIDE is now approved
We are very pleased to announce that APO®-LENALIDOMIDE is now approved by Health Canada and available in all existing strengths of lenalidomide (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg).
Apotex is proud to be delivering important savings to the Canadian Healthcare System, and to patients with Multiple Myeloma and Myelodysplastic Syndrome, with our MADE IN CANADA lenalidomide product.
APO®-LENALIDOMIDE is available through a Health Canada mandated risk management program called ApoSecureTM (similar to Revlimid’s program), to support the safe use of APO®-LENALIDOMIDE treatment by avoiding embryo-fetal exposure in pregnant women.
With the approval of APO®-LENALIDOMIDE, the ApoSecureTM portal is now live and available for patient registration.
APO®-LENALIDOMIDE is also supported by ApoAssist®, Apotex’s Patient Support Program. When a patient is enrolled into ApoSecureTM, they are automatically able to access ApoAssist® through that single point of enrolment.
ApoAssist® supports healthcare professionals and eligible patients who have been prescribed APO®-LENALIDOMIDE by facilitating drug access. Our program provides reimbursement navigation, financial assistance, and proactive initiation of coverage renewals to enable treatment continuity.
Thank you for your continued partnership in helping to provide access to affordable and high-quality medicines to Canadian patients.
For all other inquiries please contact your Apotex Representative: Julie Berdusco at firstname.lastname@example.org
Copyright © 2021. Apotex Inc.
Apotex, Apo and ApoAssist are registered trademarks owned by Apotex Inc. ApoSecure is a trademark owned by Apotex Inc.
Revlimid is a registered trademark owned by Celgene Corporation